EIKN (NASDAQ:EIKN) Coverage Initiated at Wedbush

Equities researchers at Wedbush assumed coverage on shares of EIKN (NASDAQ:EIKN) in a report released on Thursday, Marketbeat.com reports. The firm set an “underperform” rating and a $7.00 price target on the stock. Wedbush’s price objective would indicate a potential downside of 49.20% from the stock’s previous close.

Separately, Wall Street Zen raised shares of EIKN to a “hold” rating in a research report on Monday, February 16th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell” and a consensus price target of $7.00.

EIKN Trading Up 1.0%

Shares of EIKN stock opened at $13.78 on Thursday. EIKN has a 52 week low of $13.28 and a 52 week high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.